E. M. Westerman, P. P. Le-brun, D. J. Touw, H. W. Frijlink, and H. G. Heijerman, Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study, Journal of Cystic Fibrosis, vol.3, issue.1, pp.23-28, 2004.
DOI : 10.1016/j.jcf.2003.12.005

M. B. Dolovich and R. Dhand, Aerosol drug delivery: developments in device design and clinical use, The Lancet, vol.377, issue.9770, pp.1032-1045, 2011.
DOI : 10.1016/S0140-6736(10)60926-9

M. Stergiopoulou, A. Kasai, R. L. Francesconi, T. Schaufele, N. A. Sein et al., Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration-and Dose-Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis, Antimicrob. Agents Chemother, pp.53-2382, 2009.

Y. Yang, M. D. Tsifansky, C. J. Wu, H. I. Yang, G. Schmidt et al., Inhalable Antibiotic Delivery Using a Dry Powder Co-delivering Recombinant Deoxyribonuclease and Ciprofloxacin for Treatment of Cystic Fibrosis, Pharmaceutical Research, vol.33, issue.1, pp.27-151, 2010.
DOI : 10.1007/s11095-009-9991-2

M. Kumon, P. C. Kwok, H. Adi, D. Heng, and H. K. Chan, Can low-dose combination products for inhalation be formulated in single crystalline particles?, European Journal of Pharmaceutical Sciences, vol.40, issue.1, pp.40-56, 2010.
DOI : 10.1016/j.ejps.2010.02.004

D. Traini, P. Young, P. Rogueda, and R. Price, In Vitro Investigation of Drug Particulates Interactions and Aerosol Performance of Pressurised Metered Dose Inhalers, Pharmaceutical Research, vol.14, issue.1, pp.125-135, 2007.
DOI : 10.1007/s11095-006-9130-2

W. Kamin, A. Schwabe, and I. Krämer, Inhalation solutions ??? which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers, Journal of Cystic Fibrosis, vol.5, issue.4, pp.205-213, 2006.
DOI : 10.1016/j.jcf.2006.03.007

M. T. Newhouse, P. H. Hirst, S. P. Duddu, Y. H. Walter, T. E. Tarara et al., Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers, Chest, pp.124-360, 2003.

A. M. Healy, B. F. Mcdonald, L. Tajber, and O. I. Corrigan, Characterisation of excipient-free nanoporous microparticles (NPMPs) of bendroflumethiazide, European Journal of Pharmaceutics and Biopharmaceutics, vol.69, issue.3, pp.69-1182, 2008.
DOI : 10.1016/j.ejpb.2008.04.020

L. M. Nolan, L. Tajber, B. F. Mcdonald, A. S. Barham, O. I. Corrigan et al., Excipient-free nanoporous microparticles of budesonide for pulmonary delivery, European Journal of Pharmaceutical Sciences, vol.37, issue.5, pp.37-593, 2009.
DOI : 10.1016/j.ejps.2009.05.007

L. M. Nolan, J. Li, L. Tajber, O. I. Corrigan, and A. M. Healy, Particle engineering of materials for oral inhalation by dry powder inhalers. II???Sodium cromoglicate, International Journal of Pharmaceutics, vol.405, issue.1-2, pp.405-441, 2011.
DOI : 10.1016/j.ijpharm.2010.11.040

R. Donnelly and J. P. Seale, Clinical Pharmacokinetics of Inhaled Budesonide, Clinical Pharmacokinetics, vol.320, issue.6, pp.427-440, 2001.
DOI : 10.2165/00003088-200140060-00004

O. S. Usmani, K. Ito, K. Maneechotesuwan, M. Ito, M. Johnson et al., Glucocorticoid Receptor Nuclear Translocation in Airway Cells after Inhaled Combination Therapy, American Journal of Respiratory and Critical Care Medicine, vol.172, issue.6, pp.172-704, 2005.
DOI : 10.1164/rccm.200408-1041OC

P. L. Brand, Inhaled corticosteroids should be the first line of treatment for children with asthma, Paediatric Respiratory Reviews, vol.12, issue.4, pp.245-249, 2011.
DOI : 10.1016/j.prrv.2011.05.009

A. Alsaeedi, D. D. Sin, and F. A. Mcalister, The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials, The American Journal of Medicine, vol.113, issue.1, pp.113-59, 2002.
DOI : 10.1016/S0002-9343(02)01143-9

E. H. Van-haren, J. W. Lammers, J. Festen, H. G. Heijerman, C. A. Groot et al., The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis, Respiratory Medicine, vol.89, issue.3, pp.89-209, 1995.
DOI : 10.1016/0954-6111(95)90249-X

R. Dinwiddie, Anti-inflammatory therapy in cystic fibrosis, Journal of Cystic Fibrosis, vol.4, pp.45-48, 2005.
DOI : 10.1016/j.jcf.2005.05.010

K. Khanvilkar, M. D. Donovan, and D. R. Flanagan, Drug transfer through mucus, Advanced Drug Delivery Reviews, vol.48, issue.2-3, pp.48-173, 2001.
DOI : 10.1016/S0169-409X(01)00115-6

S. L. Mcgill and H. D. Smyth, Disruption of the Mucus Barrier by Topically Applied Exogenous Particles, Molecular Pharmaceutics, vol.7, issue.6, pp.2280-2288, 2010.
DOI : 10.1021/mp100242r

D. Paleari, G. A. Rossi, G. Nicolini, and D. Olivieri, Ambroxol: a multifaceted molecule with additional therapeutic potentials in respiratory disorders of childhood, Expert Opinion on Drug Discovery, vol.12, issue.2, pp.1203-1214, 2011.
DOI : 10.1111/j.1399-3038.2007.00630.x

I. Hasegawa, N. Niisato, Y. Iwasaki, and Y. Marunaka, Ambroxol-induced modification of ion transport in human airway Calu-3 epithelia, Biochemical and Biophysical Research Communications, vol.343, issue.2, pp.343-475, 2006.
DOI : 10.1016/j.bbrc.2006.03.009

Y. C. Ren, L. Wang, H. B. He, and X. Tang, Pulmonary Selectivity and Local Pharmacokinetics of Ambroxol Hydrochloride Dry Powder Inhalation in Rat, Journal of Pharmaceutical Sciences, vol.98, issue.5, pp.98-1797, 2009.
DOI : 10.1002/jps.21529

F. Tewes, L. Tajber, O. I. Corrigan, C. Ehrhardt, and A. M. Healy, Development and characterisation of soluble polymeric particles for pulmonary peptide delivery, Eur, J. Pharm. Sci, pp.41-337, 2010.

F. Tewes, O. L. Gobbo, M. I. Amaro, L. Tajber, O. I. Corrigan et al., Evaluation of HP??CD???PEG Microparticles for Salmon Calcitonin Administration via Pulmonary Delivery, Molecular Pharmaceutics, vol.8, issue.5, pp.1887-1898, 2011.
DOI : 10.1021/mp200231c

G. Borchard, M. L. Cassará, P. E. Roemelé, B. I. Florea, and H. E. Junginger, Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu???3), Journal of Pharmaceutical Sciences, vol.91, issue.6, pp.91-1561, 2002.
DOI : 10.1002/jps.10151

B. Forbes and C. Ehrhardt, Human respiratory epithelial cell culture for drug delivery applications, European Journal of Pharmaceutics and Biopharmaceutics, vol.60, issue.2, pp.193-205, 2005.
DOI : 10.1016/j.ejpb.2005.02.010

V. Caron, L. Tajber, O. I. Corrigan, and A. M. Healy, A Comparison of Spray Drying and Milling in the Production of Amorphous Dispersions of Sulfathiazole/Polyvinylpyrrolidone and Sulfadimidine/Polyvinylpyrrolidone, Molecular Pharmaceutics, vol.8, issue.2, pp.532-542, 2011.
DOI : 10.1021/mp1003674

Y. Ren, C. Yu, K. Meng, and X. Tang, Influence of Formulation and Preparation Process on Ambroxol Hydrochloride Dry Powder Inhalation Characteristics and Aerosolization Properties, Drug Development and Industrial Pharmacy, vol.28, issue.9, pp.34-984, 2008.
DOI : 10.1016/S0378-5173(00)00347-1

A. H. Chow, H. H. Tong, P. Chattopadhyay, and B. Y. Shekunov, Particle Engineering for Pulmonary Drug Delivery, Pharmaceutical Research, vol.5, issue.2, pp.411-437, 2007.
DOI : 10.1007/s11095-006-9174-3

T. M. Crowder, J. A. Rosati, J. D. Schroeter, A. J. Hickey, and T. B. Martonen, Fundamental effects of particle morphology on lung delivery: Predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development, Pharmaceutical Research, vol.19, issue.3, pp.239-245, 2002.
DOI : 10.1023/A:1014426530935

R. Lotan and . Langer, Large porous particles for pulmonary drug delivery, Science, pp.276-1868, 1997.

M. Meloun, T. Syrový, and A. Vrána, The thermodynamic dissociation constants of ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine by the regression analysis of spectrophotometric data, Talanta, vol.62, issue.3, pp.62-511, 2004.
DOI : 10.1016/j.talanta.2003.08.027

G. Akerlof, DIELECTRIC CONSTANTS OF SOME ORGANIC SOLVENT-WATER MIXTURES AT VARIOUS TEMPERATURES, Journal of the American Chemical Society, vol.54, issue.11, pp.4125-4139, 1932.
DOI : 10.1021/ja01350a001

K. Takács-novák, K. J. Box, and A. Avdeef, Potentiometric pKa determination of water-insoluble compounds: validation study in methanol/water mixtures, International Journal of Pharmaceutics, vol.151, issue.2, pp.151-235, 1997.
DOI : 10.1016/S0378-5173(97)04907-7

M. R. Caira, A. Foppoli, M. E. Sangalli, L. Zema, and F. Giordano, Thermal and structural properties of ambroxol polymorphs, Journal of Thermal Analysis and Calorimetry, vol.77, issue.2, pp.77-653, 2004.
DOI : 10.1023/B:JTAN.0000039001.05945.42

G. A. Carter, R. D. Hart, M. R. Rowles, C. E. Buckley, and M. I. Ogden, The effect of processing parameters on particle size in ammonia-induced precipitation of zirconyl chloride under industrially relevant conditions, Powder Technology, vol.191, issue.1-2, pp.191-218, 2009.
DOI : 10.1016/j.powtec.2008.10.021

J. S. Patton and P. R. Byron, Inhaling medicines: delivering drugs to the body through the lungs, Nature Reviews Drug Discovery, vol.9, issue.1, pp.67-74, 2007.
DOI : 10.1038/nrd2153

D. A. Edwards and C. Dunbar, Bioengineering of Therapeutic Aerosols, Annual Review of Biomedical Engineering, vol.4, issue.1, pp.93-107, 2002.
DOI : 10.1146/annurev.bioeng.4.100101.132311

T. Yamada, Y. Takemura, N. Niisato, E. Mitsuyama, Y. Iwasaki et al., Action of N-acylated ambroxol derivatives on secretion of chloride ions in human airway epithelia, Biochemical and Biophysical Research Communications, vol.380, issue.3, pp.380-586, 2009.
DOI : 10.1016/j.bbrc.2009.01.122

E. ?t?tinová, L. Smetanová, D. Kholová, Z. Svoboda, and J. Kv?tina, Transepithelial transport of ambroxol hydrochloride across human intestinal Caco-2 cell monolayers, General Physiology and Biophysics, vol.28, issue.3, pp.28-309, 2009.
DOI : 10.4149/gpb_2009_03_309

C. Meaney and C. O. Driscoll, Mucus as a barrier to the permeability of hydrophilic and lipophilic compounds in the absence and presence of sodium taurocholate micellar systems using cell culture models, European Journal of Pharmaceutical Sciences, vol.8, issue.3, pp.167-175, 1999.
DOI : 10.1016/S0928-0987(99)00007-X

C. I. Grainger, L. L. Greenwell, D. J. Lockley, G. P. Martin, and B. Forbes, Culture of Calu-3 Cells at the Air Interface Provides a Representative Model of the Airway Epithelial Barrier, Pharmaceutical Research, vol.26, issue.7, pp.23-1482, 2006.
DOI : 10.1007/s11095-006-0255-0